Skip to content

Anti-infective effect of non-surgical treatment with and without photodynamic therapy on peri-implantitis: a pilot multicenter prospective randomized controlled clinical trial

Anti-infective effect of non-surgical treatment with and without photodynamic therapy on peri-implantitis: a pilot multicenter prospective randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00011454
Enrollment
54
Registered
2016-12-22
Start date
2018-09-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mukositis/Periimplantitis

Interventions

Group 1: Testgroup: Scaling and Rootplaning (SRP) with hand instruments and powered dives (scaler) as well as PDT at each visit after reevaluation (each 3 months during the observation time of one yea

Sponsors

Klinik für Mund-, Kiefer- und Gesichtschirurgie im UKSH, Campus Kiel
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - ages=18. - Subjects with at least one implant with peri-implantitis. The peri-implantitis is defined as: PPD of 4-6mm combined with BOP+, and bone loss of 2-4mm on peri-apical radiographs (taken by paralleling technique with splints for reproducible X-rays) compared to the time point of restoration placement. - Availability for the 12 month duration of the study - Signed Informed Consent Form.

Exclusion criteria

Exclusion criteria: - Subject with severe systemic diseases. (e.g. uncontrolled hypertension, uncontrolled diabetes, severe coagulation disorder, acute hepatitis, acute nephritis and myocardial infarction history less than 6 months). - Pregnant or lactating females - Patients have history of periodontitis - Patients have history of receiving bisphosphonate therapy - Peri-implant mucositis defined as the absence of radiographic marginal bone loss between restoration placement and pre-screening review - Subjects treated for >2 weeks with any medication known to affect soft tissue condition (e.g. phenytoin, calcium antagonists, cyclosporin, Coumadin and non-steroidal anti-inflammatory drugs) within 1 month of the prescreening examination - Allergy to dye phenothiazine chlorid (“Toloniumchlorid or Toluidinblue“) or mouth rinse with chlorhexidine - Unwilling to participate in the study.

Design outcomes

Primary

MeasureTime frame
At baseline and after 12months: MBL: marginal bone loss - clinical record

Secondary

MeasureTime frame
At baseline and each 3months-visit during 12months: BOP%: percentage of bleeding on probing - clinical record PPD: pocket probing depth in mm - clinical record Peri-implant bacteria profile - clincal record

Countries

China, Germany

Contacts

Public ContactChristian Graetz

Klinik für Zahnerhaltung und Parodontologie im UKSH, Campus Kiel

christian.graetz@uksh.de043150026201

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026